{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:04:26Z","timestamp":1763017466587},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,19]],"date-time":"2014-11-19T00:00:00Z","timestamp":1416355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.dld.2014.09.024","type":"journal-article","created":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T16:05:30Z","timestamp":1415289930000},"page":"S212-S220","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"S5","title":["Sofosbuvir as backbone of interferon free treatments"],"prefix":"10.1016","volume":"46","author":[{"given":"Marc","family":"Bourli\u00e8re","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e8rie","family":"Oules","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Ansaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Adhoute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2014.09.024_bib0005","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0010","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0015","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0020","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0025","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0030","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1053\/j.gastro.2011.01.028","article-title":"The results of phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending","volume":"140","author":"Pawlotsky","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.09.024_bib0035","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis","volume":"147","author":"Hezode","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.09.024_bib0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0034-1371178","article-title":"New hepatitis C therapies","volume":"34","author":"Pawlotsky","year":"2014","journal-title":"Seminars in Liver Disease"},{"key":"10.1016\/j.dld.2014.09.024_bib0045","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nature Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0034-1371007","article-title":"New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development","volume":"34","author":"Pawlotsky","year":"2014","journal-title":"Seminars in Liver Disease"},{"key":"10.1016\/j.dld.2014.09.024_bib0055","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1055\/s-0034-1371008","article-title":"Interferon-combination strategies for the treatment of chronic hepatitis C","volume":"34","author":"Aronsohn","year":"2014","journal-title":"Seminars in Liver Disease"},{"key":"10.1016\/j.dld.2014.09.024_bib0060","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0065","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0070","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2014.08.018","article-title":"HCV cirrhosis at the edge of decompensation: will ABT-450\/r, ombitasvir, dasabuvir and ribavirin solve the need for treatment?","author":"Asselah","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.024_bib0080","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.10.019","article-title":"Randomized trial of daclatasvir and asunaprevir with or without PegIFN\/RBV for hepatitis C virus genotype 1 null responders","volume":"60","author":"Lok","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.024_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2014.09.024_bib0090","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.09.024_bib0095","doi-asserted-by":"crossref","first-page":"49164","DOI":"10.1074\/jbc.M305041200","article-title":"Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro","volume":"278","author":"Migliaccio","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.dld.2014.09.024_bib0100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.virol.2006.03.045","article-title":"In vitro selected Con1 subgenomic replicons resistant to 2\u2032-C-methyl-cytidine or to R1479 show lack of cross resistance","volume":"351","author":"Le Pogam","year":"2006","journal-title":"Virology"},{"issue":"Suppl.","key":"10.1016\/j.dld.2014.09.024_bib0105","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(14)60008-8","article-title":"Sofosbuvir\/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients and genotype-1 patients with prior sofosbuvir treatment experienced","volume":"60","author":"Gane","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.024_bib0110","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1053\/j.gastro.2014.04.006","article-title":"The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis","volume":"147","author":"Manns","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.09.024_bib0115","doi-asserted-by":"crossref","first-page":"S553","DOI":"10.1016\/S0168-8278(12)61416-0","article-title":"Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2or GT3 patients: SVR12 results from VITAL-1 phase 2b study","volume":"56","author":"Pawlostky","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.024_bib0120","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1128\/AAC.00016-14","article-title":"The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance","volume":"58","author":"Chatterji","year":"2014","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.dld.2014.09.024_bib0125","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0130","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/hep.26260","article-title":"Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B","volume":"57","author":"Esser-Nobis","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.024_bib0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-0034-1371009","article-title":"Interferon-free strategies with a nucleoside\/nucleotide analogue","volume":"34","author":"Feld","year":"2014","journal-title":"Seminars in Liver Disease"},{"key":"10.1016\/j.dld.2014.09.024_bib0140","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/13543784.2010.500285","article-title":"New NS5B polymerase inhibitors for hepatitis C","volume":"19","author":"Legrand-Abravanel","year":"2010","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.dld.2014.09.024_bib0145","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.1016\/S0168-8278(12)61423-8","article-title":"Interferon-free treatment with a combination of mericitabine and danoprevir\/R with or without ribavirin in treatment-naive HCV genotype 1 infected patients","volume":"56","author":"Gane","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 4","key":"10.1016\/j.dld.2014.09.024_bib0150","first-page":"849A","article-title":"Interferon-free regimen containing setrobuvir in combination with ritonavir-boosted danoprevir and ribavirin with or without mericitabine in HCV genotype 1 treatment naive patients: interim SVR4 results from the ANNAPURNA study","volume":"58","author":"Jensen","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl. 4","key":"10.1016\/j.dld.2014.09.024_bib0155","first-page":"852A","article-title":"VX-135, a once daily nucleotide HCV polymerase inhibitor was well tolerated and demonstrated potent antiviral activity when given with ribavirin in treatment naive patients with genotype1 HCV","volume":"58","author":"Papa","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.024_bib0160","doi-asserted-by":"crossref","first-page":"S528","DOI":"10.1016\/S0168-8278(14)61470-7","article-title":"An interferon and ribavirin-free 12 weeks regimen of once daily VX-135 and daclatasvir in treatment naive patients with genotype1 HCV infection","volume":"60 Suppl.","author":"Gane","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl.","key":"10.1016\/j.dld.2014.09.024_bib0165","doi-asserted-by":"crossref","first-page":"S504","DOI":"10.1016\/S0168-8278(14)61404-5","article-title":"Favorable preclinical profile of IDX-21437, a novel uridine nucleotide prodrug for use in a direct-acting antiviral regimen for HCV","volume":"60","author":"Gupta","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.024_bib0170","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a beta-d-2\u2032-deoxy-2\u2032-alpha-fluoro-2\u2032-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.dld.2014.09.024_bib0175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/gutjnl-2013-305771","article-title":"New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C","volume":"63","author":"Marino","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2014.09.024_bib0180","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl.","key":"10.1016\/j.dld.2014.09.024_bib0185","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1016\/S0168-8278(13)60847-8","article-title":"Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with HCV infection: the QUANTUM study","volume":"58","author":"Lalezari","year":"2013","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.024_bib0190","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","article-title":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial","volume":"310","author":"Osinusi","year":"2013","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/j.dld.2014.09.024_bib0195","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA: The Journal of the American Medical Association"},{"issue":"Suppl.","key":"10.1016\/j.dld.2014.09.024_bib0200","first-page":"314A","article-title":"Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation","volume":"58","author":"Curry","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl.","key":"10.1016\/j.dld.2014.09.024_bib0205","doi-asserted-by":"crossref","first-page":"S499","DOI":"10.1016\/S0168-8278(14)61392-1","article-title":"Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective multicenter study","volume":"60","author":"Samuel","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.024_bib0210","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2014.09.024_bib0215","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0220","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2014.09.024_bib0225","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0230","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0235","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl.","key":"10.1016\/j.dld.2014.09.024_bib0240","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0168-8278(14)60016-7","article-title":"Use of sofosbuvir\/ledipasvir fixed dose combination for treatment of HCV genotype-1 in patients coinfected with HIV","volume":"60","author":"Osinusi","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.09.024_bib0245","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0168-8278(14)60013-1","article-title":"Retreatment of relapsers to sofosbuvir\/ribavirin with sofosbuvir\/ledipasvir: complete and rapid virologic suppression by week 4","volume":"60","author":"Osinusi","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl.","key":"10.1016\/j.dld.2014.09.024_bib0250","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0168-8278(14)60113-6","article-title":"Safety and efficacy of treatment with the interferon-free, ribavirin-free combination of sofosbuvir+GS-5816 for 12 weeks in treatment naive patients with genotype 1-6 HCV patients","volume":"60","author":"Everson","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl.","key":"10.1016\/j.dld.2014.09.024_bib0255","first-page":"243A","article-title":"Once daily sofosbuvir\/ledipasvir fixed dose combination with or without ribavirin: the ELECTRON trial","volume":"58","author":"Gane","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.09.024_bib0260","series-title":"Programs and abstracts of the 21st conference on retroviruses and opportunistic infections","article-title":"Combination oral hepatitis C antiviral therapy for 6 or 12 weeks: results of the SYNERGY trial","author":"Kohli","year":"2014"},{"key":"10.1016\/j.dld.2014.09.024_bib0265","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0270","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0275","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.09.024_bib0280","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"60","author":"European Association for Study of Liver","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl.","key":"10.1016\/j.dld.2014.09.024_bib0285","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(14)60010-6","article-title":"Successful retreatment with sofosbuvir-containing regimen for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy","volume":"60","author":"Esteban","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl.","key":"10.1016\/j.dld.2014.09.024_bib0290","doi-asserted-by":"crossref","first-page":"S503","DOI":"10.1016\/S0168-8278(14)61403-3","article-title":"Sofosbuvir plus ribavirin, an interferon-free regimen in the treatment of treatment-naive and treatment-experienced patients with chronic genotype 4 HCV infection","volume":"60","author":"Ruane","year":"2014","journal-title":"Journal of Hepatology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865814007221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865814007221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T19:56:29Z","timestamp":1538078189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865814007221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":58,"alternative-id":["S1590865814007221"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2014.09.024","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sofosbuvir as backbone of interferon free treatments","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2014.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}